• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙型肝炎核心抗原在对抗丙型肝炎病毒方面发挥着重要作用,可以作为丙型肝炎病毒 RNA 检测的替代方法。

HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection.

机构信息

Department of Transfusion, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

出版信息

J Clin Lab Anal. 2021 Jun;35(6):e23755. doi: 10.1002/jcla.23755. Epub 2021 Mar 31.

DOI:10.1002/jcla.23755
PMID:33788295
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8183919/
Abstract

OBJECTIVE

To discuss the clinical significance of HCV-cAg testing in the diagnosis, activity determination, and monitoring of therapeutic effectiveness of HCV infection and its advantages compared with HCV-RNA and anti-HCV antibodies detection.

METHODS

By summarizing the published literature, the advantages and significance of HCV core antigen detection were sought.

RESULTS

The expression of HCV-cAg is highly consistent with that of HCV-RNA, but compared with HCV-RNA, detection of HCV-cAg is easy to operate, time saving, and low cost. HCV-cAg can be detected within 1215 days after infection, and the window period can be shortened by57 weeks. HCV-cAg is a serological indicator of virus replication, which can distinguish previous infection of HCV or current infection. HCV-cAg detection is more suitable for immunocompromised, hemodialysis, organ transplant patients. HCV-cAg also can be used to monitor antiviral efficacy and predict sustained virological response (SVR).

CONCLUSION

HCV core antigen has similar clinical sensitivity to NAT and can be used as a substitute for HCV-RNA in the diagnosis of virus infection. Combined detection of HCV-cAg and antibody serology can help doctors detect HCV infection earlier, accurately diagnose different stages of HCV infection, and evaluate the therapeutic effect of antiviral drugs, which are beneficial in the prevention and treatment of hepatitis C.

摘要

目的

探讨丙型肝炎病毒核心抗原(HCV-cAg)检测在丙型肝炎病毒(HCV)感染的诊断、活动度判断和疗效监测中的临床意义,并与 HCV-RNA 和抗-HCV 抗体检测进行比较。

方法

通过查阅已发表的文献,总结 HCV-cAg 检测的优势和意义。

结果

HCV-cAg 的表达与 HCV-RNA 高度一致,但与 HCV-RNA 相比,HCV-cAg 检测操作简便、省时、成本低。HCV-cAg 可在感染后 1215 天内检出,可将窗口期缩短 57 周。HCV-cAg 是病毒复制的血清学指标,可区分 HCV 的既往感染或现症感染。HCV-cAg 检测更适用于免疫功能低下、血液透析、器官移植患者。HCV-cAg 还可用于监测抗病毒疗效和预测持续病毒学应答(SVR)。

结论

HCV-cAg 的临床灵敏度与 NAT 相似,可替代 HCV-RNA 用于病毒感染的诊断。HCV-cAg 与抗体血清学联合检测有助于医生更早地发现 HCV 感染,准确诊断 HCV 感染的不同阶段,评估抗病毒药物的治疗效果,有利于丙型肝炎的防治。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/707a/8183919/dff00210667f/JCLA-35-e23755-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/707a/8183919/dff00210667f/JCLA-35-e23755-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/707a/8183919/dff00210667f/JCLA-35-e23755-g001.jpg

相似文献

1
HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection.丙型肝炎核心抗原在对抗丙型肝炎病毒方面发挥着重要作用,可以作为丙型肝炎病毒 RNA 检测的替代方法。
J Clin Lab Anal. 2021 Jun;35(6):e23755. doi: 10.1002/jcla.23755. Epub 2021 Mar 31.
2
HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.直接作用抗病毒药物时代 HCV 核心抗原替代 HCV RNA 检测:回顾性筛查和诊断队列研究。
Lancet Gastroenterol Hepatol. 2018 Dec;3(12):856-864. doi: 10.1016/S2468-1253(18)30271-1. Epub 2018 Sep 28.
3
Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment.丙型肝炎病毒核心抗原检测:在诊断、疾病监测及治疗中的作用
World J Gastroenterol. 2014 Jun 14;20(22):6701-6. doi: 10.3748/wjg.v20.i22.6701.
4
Detection of hepatitis C core antigen in the antibody negative 'window' phase of hepatitis C infection.丙型肝炎感染抗体阴性“窗口期”丙型肝炎核心抗原的检测
Vox Sang. 2000;78(2):80-5. doi: 10.1159/000031155.
5
The potential role of HCV core antigen testing in diagnosing HCV infection.丙型肝炎病毒核心抗原检测在诊断丙型肝炎病毒感染中的潜在作用。
Antivir Ther. 2012;17(7 Pt B):1431-5. doi: 10.3851/IMP2463. Epub 2012 Dec 7.
6
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.丙型肝炎病毒核心抗原作为丙型肝炎病毒RNA的替代检测方法,用于评估丙型肝炎病毒1型感染患者对全口服、无干扰素治疗的病毒学反应。
J Virol Methods. 2017 Jul;245:14-18. doi: 10.1016/j.jviromet.2017.03.002. Epub 2017 Mar 27.
7
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.丙型肝炎病毒核心抗原:一种简化的治疗监测工具,包括用于治疗后复发的情况。
J Clin Virol. 2017 Jul;92:32-38. doi: 10.1016/j.jcv.2017.05.007. Epub 2017 May 11.
8
Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyzer.在全自动化学发光分析仪上进行丙型肝炎病毒核心抗原和抗体联合检测。
Transfusion. 2003 Aug;43(8):1067-74. doi: 10.1046/j.1537-2995.2003.00482.x.
9
Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.在干扰素联合利巴韦林治疗慢性丙型肝炎患者期间,对总丙型肝炎病毒核心抗原检测、分支DNA检测和Amplicor监测检测在确定病毒血症方面的比较评估。
J Clin Microbiol. 2003 Jul;41(7):3212-20. doi: 10.1128/JCM.41.7.3212-3220.2003.
10
Hepatitis C virus core antigen: A diagnostic and treatment monitoring marker of hepatitis C virus in Indian population.丙型肝炎病毒核心抗原:印度人群丙型肝炎病毒的诊断和治疗监测标志物。
Indian J Gastroenterol. 2024 Aug;43(4):799-804. doi: 10.1007/s12664-024-01549-7. Epub 2024 Apr 15.

引用本文的文献

1
Predicting hepatitis C infection via machine learning.通过机器学习预测丙型肝炎感染
Am J Transl Res. 2025 Jul 15;17(7):5120-5128. doi: 10.62347/QXZB5406. eCollection 2025.
2
A scoping review on HCV screening strategies: population to screen and the test types.关于丙型肝炎病毒(HCV)筛查策略的范围综述:筛查人群及检测类型
BMC Public Health. 2025 Jul 30;25(1):2589. doi: 10.1186/s12889-025-23809-7.
3
Hepatitis C Virus-Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes.丙型肝炎病毒核心抗原:在诊断、治疗监测及临床结局中的意义

本文引用的文献

1
Hepatitis C core antigen testing to diagnose active hepatitis C infection among haemodialysis patients.丙型肝炎核心抗原检测用于诊断血液透析患者中的活动性丙型肝炎感染。
BMC Nephrol. 2020 Nov 13;21(1):480. doi: 10.1186/s12882-020-02154-4.
2
Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community.在 HCV 流行地区,抗-HCV 反射 HCV Ag 筛查策略的可行性。
J Formos Med Assoc. 2021 May;120(5):1237-1241. doi: 10.1016/j.jfma.2020.09.013. Epub 2020 Sep 30.
3
Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype.
Viruses. 2024 Nov 29;16(12):1863. doi: 10.3390/v16121863.
4
Diagnostic performance of hepatitis C virus core antigen testing for detecting hepatitis C in people living with hepatitis B: a systematic review and meta-analysis.丙型肝炎病毒核心抗原检测在乙型肝炎患者中检测丙型肝炎的诊断性能:一项系统评价和荟萃分析
Infect Dis Poverty. 2024 Dec 2;13(1):89. doi: 10.1186/s40249-024-01264-7.
5
Comparison of anti-HCV combined with HCVcAg (Elecsys HCV Duo immunoassay) and anti-HCV rapid test followed by HCV RNA analysis using qRT-PCR to identify active infection for treatment.对比抗-HCV 联合 HCVcAg(Elecsys HCV Duo 免疫分析法)与抗-HCV 快速检测,随后采用 qRT-PCR 分析 HCV RNA 以确定治疗的活动性感染。
PLoS One. 2024 Nov 18;19(11):e0313771. doi: 10.1371/journal.pone.0313771. eCollection 2024.
6
Performance of Elecsys HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection.Elecsys HCV Duo免疫测定法在诊断和评估合并或未合并HIV感染的丙型肝炎患者治疗反应中的性能
Diagnostics (Basel). 2024 Sep 29;14(19):2179. doi: 10.3390/diagnostics14192179.
7
Biomarkers in Detection of Hepatitis C Virus Infection.丙型肝炎病毒感染检测中的生物标志物
Pathogens. 2024 Apr 17;13(4):331. doi: 10.3390/pathogens13040331.
8
HCV Genotype Distribution and Clinical Characteristics of HCV Mono-Infected and HCV/HIV Co-Infected Patients in Liangshan Prefecture, Sichuan Province, China.中国四川省凉山州 HCV 单感染和 HCV/HIV 共感染患者的 HCV 基因型分布及临床特征。
J Int Assoc Provid AIDS Care. 2023 Jan-Dec;22:23259582231217810. doi: 10.1177/23259582231217810.
9
The Study of Performance of a Nanoribbon Biosensor, Sensitized with Aptamers and Antibodies, upon Detection of Core Antigen of Hepatitis C Virus.用适体和抗体敏化的纳米带生物传感器检测丙型肝炎病毒核心抗原的性能研究
Micromachines (Basel). 2023 Oct 19;14(10):1946. doi: 10.3390/mi14101946.
10
What Hepatitis C Virus (HCV) Diagnostic Tools Are Needed to Advance Diagnosis of Current HCV Infection in Outreach Settings and in a Nonclinical Setting?在普及环境和非临床环境中,需要哪些丙型肝炎病毒(HCV)诊断工具来推进当前 HCV 感染的诊断?
J Infect Dis. 2024 May 8;229(Supplement_3):S328-S333. doi: 10.1093/infdis/jiad269.
HCV 核心抗原作为 HCV RNA 检测替代物的实际应用:对病毒载量和基因型的影响。
J Viral Hepat. 2020 Oct;27(10):996-1002. doi: 10.1111/jvh.13337. Epub 2020 Jul 1.
4
Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.丙型肝炎病毒核心抗原检测在直接作用抗病毒药物治疗慢性丙型肝炎中的临床应用。
PLoS One. 2020 Mar 3;15(3):e0229994. doi: 10.1371/journal.pone.0229994. eCollection 2020.
5
Design of a novel rapid immunoassay for simultaneous detection of hepatitis C virus core antigen and antibodies.新型丙型肝炎病毒核心抗原和抗体同时检测免疫分析方法的设计。
Arch Virol. 2020 Mar;165(3):627-641. doi: 10.1007/s00705-019-04518-0. Epub 2020 Jan 21.
6
Implications of grey zone results for routine hepatitis C virus screening with the ARCHITECT HCV-Ag assay.ARCHITECT HCV-Ag 检测用于丙型肝炎病毒常规筛查时灰区结果的意义。
J Appl Microbiol. 2020 Mar;128(3):899-906. doi: 10.1111/jam.14517. Epub 2019 Nov 28.
7
Seronegative hepatitis C virus infection in Polish blood donors-Virological characteristics of index donations and follow-up observations.波兰献血者中丙型肝炎病毒血清阴性感染 - 索引献血和随访观察的病毒学特征。
J Med Virol. 2020 Mar;92(3):339-347. doi: 10.1002/jmv.25617. Epub 2019 Nov 21.
8
Hepatitis C core antigen: Diagnosis and monitoring of patients infected with hepatitis C virus.丙型肝炎核心抗原:丙型肝炎病毒感染者的诊断和监测。
Int J Infect Dis. 2019 Dec;89:131-136. doi: 10.1016/j.ijid.2019.09.022. Epub 2019 Sep 30.
9
Hepatitis C Core-Antigen Testing from Dried Blood Spots.丙型肝炎核心抗原检测(干血斑法)
Viruses. 2019 Sep 6;11(9):830. doi: 10.3390/v11090830.
10
Community screening for hepatitis C virus infection in a low-prevalence population.在低流行人群中进行丙型肝炎病毒感染的社区筛查。
BMC Public Health. 2019 Aug 2;19(1):1038. doi: 10.1186/s12889-019-7388-7.